vs
Amphastar Pharmaceuticals, Inc.（AMPH）とフォトロニクス（PLAB）の財務データ比較。上の社名をクリックして会社を切り替えられます
フォトロニクスの直近四半期売上が大きい（$210.4M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.1倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 10.9%、差は2.5%）。Amphastar Pharmaceuticals, Inc.の前年同期比売上増加率が高い（-1.8% vs -5.5%）。フォトロニクスの直近四半期フリーキャッシュフローが多い（$25.2M vs $24.6M）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs -3.8%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
フォトロニクスは米国の半導体フォトマスクメーカーで、2009年時点で世界第3位のフォトマスクサプライヤーです。電子ビームイニシアチブのメンバーでもあり、半導体製造に不可欠なフォトマスクを供給し、チップ製造の回路パターン転写工程を支えています。
AMPH vs PLAB — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $210.4M |
| 純利益 | $24.4M | $22.9M |
| 粗利率 | 46.8% | 33.7% |
| 営業利益率 | 19.4% | 22.9% |
| 純利益率 | 13.3% | 10.9% |
| 売上前年比 | -1.8% | -5.5% |
| 純利益前年比 | -35.7% | -32.4% |
| EPS（希薄化後） | $0.51 | $0.39 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | — | ||
| Q3 25 | $191.8M | $210.4M | ||
| Q2 25 | $174.4M | $211.0M | ||
| Q1 25 | $170.5M | $212.1M | ||
| Q4 24 | $186.5M | $222.6M | ||
| Q3 24 | $191.2M | $211.0M | ||
| Q2 24 | $182.4M | $217.0M | ||
| Q1 24 | $171.8M | $216.3M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $22.9M | ||
| Q2 25 | $31.0M | $8.9M | ||
| Q1 25 | $25.3M | $42.9M | ||
| Q4 24 | $38.0M | $33.9M | ||
| Q3 24 | $40.4M | $34.4M | ||
| Q2 24 | $37.9M | $36.3M | ||
| Q1 24 | $43.2M | $26.2M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | 33.7% | ||
| Q2 25 | 49.6% | 36.9% | ||
| Q1 25 | 50.0% | 35.6% | ||
| Q4 24 | 46.5% | 37.0% | ||
| Q3 24 | 53.3% | 35.6% | ||
| Q2 24 | 52.2% | 36.5% | ||
| Q1 24 | 52.4% | 36.6% |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 13.2% | 22.9% | ||
| Q2 25 | 24.2% | 26.4% | ||
| Q1 25 | 21.9% | 24.6% | ||
| Q4 24 | 24.2% | 25.1% | ||
| Q3 24 | 29.8% | 24.7% | ||
| Q2 24 | 30.3% | 25.8% | ||
| Q1 24 | 27.9% | 26.6% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 10.9% | ||
| Q2 25 | 17.8% | 4.2% | ||
| Q1 25 | 14.8% | 20.2% | ||
| Q4 24 | 20.4% | 15.2% | ||
| Q3 24 | 21.1% | 16.3% | ||
| Q2 24 | 20.8% | 16.7% | ||
| Q1 24 | 25.1% | 12.1% |
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | $0.39 | ||
| Q2 25 | $0.64 | $0.15 | ||
| Q1 25 | $0.51 | $0.68 | ||
| Q4 24 | $0.74 | $0.54 | ||
| Q3 24 | $0.78 | $0.55 | ||
| Q2 24 | $0.73 | $0.58 | ||
| Q1 24 | $0.81 | $0.42 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $575.8M |
| 総負債低いほど良い | $608.7M | $16.0K |
| 株主資本純資産 | $788.8M | $1.1B |
| 総資産 | $1.6B | $1.8B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 0.00× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | $575.8M | ||
| Q2 25 | $231.8M | $558.4M | ||
| Q1 25 | $236.9M | $642.2M | ||
| Q4 24 | $221.6M | $640.7M | ||
| Q3 24 | $250.5M | $606.4M | ||
| Q2 24 | $217.8M | $559.9M | ||
| Q1 24 | $289.6M | $521.5M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | $16.0K | ||
| Q2 25 | $607.7M | $19.0K | ||
| Q1 25 | $603.9M | $21.0K | ||
| Q4 24 | $601.6M | $25.0K | ||
| Q3 24 | $596.4M | $28.0K | ||
| Q2 24 | $586.9M | $2.5M | ||
| Q1 24 | $594.0M | $2.7M |
| Q4 25 | $788.8M | — | ||
| Q3 25 | $776.7M | $1.1B | ||
| Q2 25 | $757.5M | $1.1B | ||
| Q1 25 | $751.3M | $1.1B | ||
| Q4 24 | $732.3M | $1.1B | ||
| Q3 24 | $727.7M | $1.1B | ||
| Q2 24 | $713.3M | $1.0B | ||
| Q1 24 | $672.4M | $1.0B |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.7B | $1.8B | ||
| Q2 25 | $1.6B | $1.7B | ||
| Q1 25 | $1.6B | $1.7B | ||
| Q4 24 | $1.6B | $1.7B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.6B | $1.6B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | 0.00× | ||
| Q2 25 | 0.80× | 0.00× | ||
| Q1 25 | 0.80× | 0.00× | ||
| Q4 24 | 0.82× | 0.00× | ||
| Q3 24 | 0.82× | 0.00× | ||
| Q2 24 | 0.82× | 0.00× | ||
| Q1 24 | 0.88× | 0.00× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $50.1M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $25.2M |
| FCFマージンFCF / 売上 | 13.4% | 12.0% |
| 設備投資強度設備投資 / 売上 | 4.5% | 11.8% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 2.19× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $64.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | — | ||
| Q3 25 | $52.6M | $50.1M | ||
| Q2 25 | $35.6M | $31.5M | ||
| Q1 25 | $35.1M | $78.5M | ||
| Q4 24 | $29.0M | $68.4M | ||
| Q3 24 | $60.0M | $75.1M | ||
| Q2 24 | $69.1M | $76.5M | ||
| Q1 24 | $55.3M | $41.5M |
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | $25.2M | ||
| Q2 25 | $25.0M | $-29.1M | ||
| Q1 25 | $24.4M | $43.3M | ||
| Q4 24 | $16.6M | $25.2M | ||
| Q3 24 | $46.2M | $50.7M | ||
| Q2 24 | $63.1M | $56.5M | ||
| Q1 24 | $46.5M | $-1.8M |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | 12.0% | ||
| Q2 25 | 14.3% | -13.8% | ||
| Q1 25 | 14.3% | 20.4% | ||
| Q4 24 | 8.9% | 11.3% | ||
| Q3 24 | 24.1% | 24.0% | ||
| Q2 24 | 34.6% | 26.0% | ||
| Q1 24 | 27.1% | -0.8% |
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | 11.8% | ||
| Q2 25 | 6.1% | 28.7% | ||
| Q1 25 | 6.3% | 16.6% | ||
| Q4 24 | 6.7% | 19.4% | ||
| Q3 24 | 7.2% | 11.6% | ||
| Q2 24 | 3.3% | 9.2% | ||
| Q1 24 | 5.1% | 20.0% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 2.19× | ||
| Q2 25 | 1.15× | 3.55× | ||
| Q1 25 | 1.39× | 1.83× | ||
| Q4 24 | 0.76× | 2.02× | ||
| Q3 24 | 1.48× | 2.18× | ||
| Q2 24 | 1.82× | 2.11× | ||
| Q1 24 | 1.28× | 1.59× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PLAB
| High End Integrated Circuits | $53.6M | 25% |
| High End Flat Panel Displays | $53.5M | 25% |
| KR | $43.7M | 21% |
| Other | $42.1M | 20% |
| Mainstream Flat Panel Displays | $9.1M | 4% |
| Transferred At Point In Time | $8.4M | 4% |
